With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...

New Delhi: Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net ...

Stocks including Titan Company, Dr Reddy's Labs, NTPC, Tata Steel, Infosys, GAIL (India), Hero Motocorp, Mankind Pharma and ...

Indian shares are set to open flat on Wednesday, with caution likely to prevail as U.S. presidential election results trickle in. The Gift Nifty futures were trading at 24,268, as of 07:48 ...

Its consolidated profit after tax rose 17 per cent. Dr. Reddy’s Laboratories’ consolidated revenue was up 16.5 per cent to Rs ...

Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the green. Nifty 50 closed at 24,213.30, ...

The Board of Directors of Dr. Reddys Laboratories Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 ...

Pharma exporters like Sun Pharmaceuticals Industries Ltd., Dr Reddy's Laboratories Ltd., Divi's Laboratories Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd. and Lupin Ltd. and Laurus Labs Ltd.

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.

Much like the trend in the domestic pharma industry, Dr Reddy's Laboratories is investing heavily in research and development aimed at ramping up the biosimilars, generics, and biologics segments. In ...

HYDERABAD: Pharma major Dr Reddy's Laboratories on Tuesday reported a 15% drop in consolidated net profit for the Sept ...

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up over 85% of the firm's sales, and along with other generics manufacturers, it continues to suffer low ...